Retatrutide vs Semaglutide vs Tirzepatide Naming Conventions
A side-by-side look at how retatrutide, semaglutide, and tirzepatide are named in listings, INN stems, and vial labels, and why the terms are easy to mix up.
Anika Patel, MD, MPH is a board-certified physician with a Master of Public Health from Harvard T.H. Chan School of Public Health whose research bridges internal medicine, obesity medicine, and the public health implications of novel peptide therapeutics.
Retatrutide, semaglutide, and tirzepatide share a naming family but not a naming logic, and the differences explain most of the confusion that shows up in listings and forum threads. All three end in “-tide,” a nod to their peptide structure, but the syllables before that suffix encode different things depending on which naming system generated them. Understanding retatrutide vs semaglutide vs tirzepatide naming conventions means separating three layers: the international nonproprietary name (INN) stem, the way suppliers write listing titles, and the shorthand that vial labels use for concentration. Each layer follows its own rules, and mixing them up is where most mislabeling confusion starts.
The INN Layer: What the Stems Actually Encode
International nonproprietary names are built from a root plus a stem that signals a pharmacological class. “-tide” broadly marks a peptide. Within that, the letters immediately before the stem are not decorative. Semaglutide and tirzepatide both trace to the GLP-1 receptor family lineage, but tirzepatide’s name was constructed to reflect a dual mechanism spanning GLP-1 and GIP receptor activity, which is part of why its root doesn’t parallel semaglutide’s root syllable for syllable. Retatrutide extends this further: its name reflects a design that engages a third receptor pathway, glucagon, alongside GLP-1 and GIP. The naming committees that assign INNs try to keep stems consistent within a class so that a reader familiar with the convention can guess a compound’s general category from the name alone, but they do not encode potency, formulation, or dose in the name. That information lives elsewhere, and listings that imply otherwise are stretching what the name actually says.
How Listings Write These Names Differently
Supplier and marketplace listings rarely use the INN in isolation. A title might read “Retatrutide 10mg” or “Tirzepatide Peptide Vial 5mg/2mL,” and the formatting choices vary by site. Some listings put the concentration expression directly in the title; others push it to a subhead or a separate spec table. This is a listing convention, not a pharmacological one, and it means two vials with identical contents can be titled in visibly different ways depending on which supplier wrote the copy. The naming pattern also tends to be more consistent for semaglutide and tirzepatide, which have been listed longer and have settled into a fairly standard “compound name + total mg + vial size” format. Retatrutide listings are newer and less standardized, so titles for it show more variation in whether the total mg, the per-mL concentration, or both are surfaced in the name itself.
Vial Labels: Concentration Language, Not Dose Language
Vial labels describe what is inside the vial as manufactured, not what a syringe draw represents. A label reading “10 mg” states the total peptide mass sealed in that vial before any diluent is added. Once bacteriostatic water is added, the resulting concentration is a separate calculation, and reading vial labels correctly means keeping those two numbers apart. The relationship is straightforward: concentration equals the total milligrams in the vial divided by the milliliters of diluent added.
A Worked Example of Reading Two Labels Side by Side
Take a vial labeled “Retatrutide 10 mg” and a vial labeled “Tirzepatide 10 mg” that are reconstituted differently. If the retatrutide vial receives 2 mL of bacteriostatic water, the resulting concentration is 10 mg ÷ 2 mL = 5 mg/mL. If the tirzepatide vial receives 1 mL instead, its concentration is 10 mg ÷ 1 mL = 10 mg/mL. Converted to mcg, since 1 mg equals 1000 mcg, the first solution holds 5000 mcg per mL and the second holds 10,000 mcg per mL. On a U-100 insulin syringe, where 1 mL corresponds to 100 unit marks, the first vial delivers roughly 50 mcg per unit mark (5000 mcg ÷ 100 units) and the second delivers roughly 100 mcg per unit mark (10,000 mcg ÷ 100 units). Neither number appears anywhere in the compound’s name. Both come entirely from how much diluent was added, which is why a label reading “10 mg” tells a reader almost nothing about concentration until the reconstitution volume is specified alongside it. Readers checking this kind of arithmetic against their own vial specifics often cross-reference a calculator such as peptcalc.com rather than doing the division by hand each time.
A Side-by-Side Comparison
| Attribute | Retatrutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptor pathways referenced in design | GLP-1, GIP, glucagon | GLP-1 | GLP-1, GIP |
| INN suffix | -tide | -tide | -tide |
| Typical listing format | Compound + mg, less standardized | Compound + mg + vial size | Compound + mg + vial size |
| How long the naming pattern has been in common use | Shorter | Longer | Longer |
| What the name alone tells you about concentration | Nothing | Nothing | Nothing |
Why the Confusion Persists
Part of the naming confusion in this space comes from suppliers copying title formats across compounds without adjusting for how new or established each one is in the marketplace. A retatrutide listing might borrow the exact title structure a supplier already uses for tirzepatide, even though the underlying compound family and receptor design differ. Sites that track pricing patterns across these three compounds, including cost breakdowns like the ones covered at retacost.com, tend to normalize listings back to a per-mg or per-mL basis specifically because the raw title text is inconsistent enough that comparing titles directly is unreliable. Naming conventions also interact with sourcing breadth: a catalogue that lists dozens of related compounds, such as the one at heezresearch.com/, has to apply some internal consistency to its own titles just to keep the listings navigable, which is a different problem than what any single vial label is required to disclose.
Terminology That Gets Conflated
A few terms get used interchangeably in casual discussion even though they mean distinct things. “Concentration” refers to mg per mL after reconstitution. “Total content” refers to the mg sealed in the vial before any water is added. “Dose” refers to whatever amount a protocol specifies, which is a separate figure from either of the above and is not something this article addresses. Listings that blur these terms, intentionally or not, are a naming problem layered on top of the INN and vial-label layers already discussed. Reference material that catalogs how these terms are used across the retatrutide-focused corner of the market, such as retainfo.com, is one way to cross-check a listing’s terminology against a more consistent baseline before taking any single title at face value.
Summary
Retatrutide, semaglutide, and tirzepatide share a peptide naming suffix but diverge in INN stem logic, listing format maturity, and how consistently suppliers write vial titles. None of the three names encode concentration or dose; that information only emerges once total vial content is divided by diluent volume, as the worked example above shows. Reading a listing accurately means separating what the compound’s name tells you, what the listing format happens to show, and what the vial label states as manufactured content, since those three layers are governed by different conventions and none of them substitute for the others.